Entero Therapeutics, Inc. — Director's Dealing 2024

Jan 17, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: First Wave BioPharma, Inc. (FWBI)
CIK: 0001604191
Period of Report: 2024-01-12

Reporting Person: SAPIRSTEIN JAMES (Director, Chairman, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-01-12	Common Stock	S	166	$4.20	Disposed	39166	Direct

Footnotes

F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2: Includes unvested RSUs.